STOCK TITAN

Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

SAN DIEGO--(BUSINESS WIRE)-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nine months ended September 30, 2021 after the market closes on Monday, November 15, 2021. The Company will host an investor conference call to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Date/Time:

Monday, November 15, 4:30 p.m. ET / 1:30 p.m. PT

 

Pre-Registration:

Participants can pre-register for the conference call here.

 

Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

 

Dial In:

Those who choose not to pre-register can access the live conference call by dialing the following and requesting the Biocept call:

U.S. Callers:

855-656-0927

Canadian Callers:

855-669-9657

Other International Callers:

412-902-4109

A live webcast of the call will be available at https://ir.biocept.com/. The webcast will be archived for 90 days.

A replay of the conference call will be available for 48 hours following the conclusion of the call by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers, or (412) 317-0088 for other international callers, and entering the replay access code 10161580.

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept’s patented Target Selector™ technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

LHA Investor Relations

Jody Cain

Jcain@lhai.com

310-691-7100

Source: Biocept, Inc.

Biocept Inc

NASDAQ:BIOC

BIOC Rankings

BIOC Latest News

BIOC Stock Data

Medical Laboratories
Health Care and Social Assistance
Link
Health Technology, Biotechnology, Commercial Services, Miscellaneous Commercial Services, Health Services, Medical/Nursing Services, Health Care and Social Assistance, Medical Laboratories
US
San Diego

About BIOC

biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar